Bj. Monk et al., EXPANDED POLYTETRAFLUOROETHYLENE IS AN EFFECTIVE BARRIER IN PREVENTING PELVIC ADHESIONS AFTER RADICAL SURGERY FOR OVARIAN-CANCER, International journal of gynecological cancer, 8(5), 1998, pp. 403-408
Objective: To determine the efficacy of expanded polytetrafluoroethyle
ne(ePTFE) in preventing pelvic adhesions following primary surgical de
bulking of epithelial ovarian cancer. Methods: Twenty-one patients wit
h advanced ovarian cancer undergoing optimal debulking including excis
ion of the pelvic peritoneum were randomized intraoperatively to eithe
r a control group or to a subset undergoing coverage of the pelvic per
itoneal defect with ePTFE. Following chemotherapy, a second look proce
dure was performed and adhesions scored. The pelvis was divided into q
uadrants, and each quadrant was assessed for the extent and type of ad
hesion involvement (avascular, vascular, thick) and given a composite
score (range 0-20). In addition, any visceral structures involved with
adhesions were noted. The number of quadrants involved with adhesions
and the mean adhesion scores between the control and experimental gro
up were compared using a two-tailed Fisher's exact and t-test, respect
ively. Results: Thirteen patients (six ePTFE recipients and seven-cont
rols) were evaluable and underwent surgical reassessment while six eit
her refused second look (N = 2) and/or chemotherapy (AT = 2) or progre
ssed (N = 2). One patient in both the ePTFE and control groups died of
disease prior to reassessment. Forty-two percent (10 of 24) of the pe
lvic quadrants covered with ePTFE contained adhesions compared to 86%
(24 of 28) in the control group (P = 0.001). The mean total quadrant a
dhesion score was also lower when ePTFE was used, 1.6 +/- 3.2 (range 0
-8) vs 8.7 +/- 5.7 (range 2-17) (P = 0.01). The incidence of bowel loo
p adhesions, organ/ structure involvement and postoperative complicati
ons was similar in both groups. Conclusions: An ePTFE membrane is effe
ctive in preventing pelvic adhesions after radical debulking for ovari
an cancer. The clinical implications associated with its use, however,
require further study.